The new purchase will enable Acceleron to gather safe dosing and pharmcodynamic activity information vital to future studies of ACE-031. To find out more on these ongoing studies, visit clinicaltrials.query and gov study identifiers NCT01099761 and NCT01239758. MDA is pleased to support Acceleron’s initiatives in the fight against Duchenne Muscular Dystrophy, stated Valerie Cwik, M.D., MDA Executive Vice President – Analysis and Medical Director. Our strategic purchase should help Acceleron expedite the next phase of ACE-031 human clinical trials. .. Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy Acceleron Pharma, Inc., a biopharmaceutical firm developing novel therapeutics that modulate the development of tissues and cells including muscles, bone, fat, red blood cells and the vasculature, today announced it has been awarded a $1.5 million grant from the Muscular Dystrophy Association to aid clinical studies of ACE-031 in Duchenne Muscular Dystrophy , a disabling neuromuscular disease where patients knowledge a progressive loss of muscle power and mass.The potential for confounding remains; however, it really is unlikely that the magnitude of the decrease in bleeding rates with prophylaxis as compared with episodic treatment is the consequence of confounding alone. This scholarly study had not been designed to compare the two prophylactic regimens. Both the weekly dosing and interval-altered dosing regimens led to significantly reduced annualized prices of bleeding, in comparison with episodic treatment. Whether one method of dosing is more advanced than the other cannot be determined on the basis of this study.